



**The proteasome inhibitor bortezomib induces
schedule-dependent modulation of gemcitabine
pharmacokinetics and pharmacodynamics in
non-small cell lung cancer and peripheral blood
mononuclear cells**

Cecilia Ceresa*, Elisa Giovannetti*, Jens Voortman, Adrie C Laan,
Richard Honeywell, Giuseppe Giaccone and Godefridus J Peters

Submitted

* Equally contributed